David Fruman, Ph.D.
The Fruman Lab studies signal transduction and metabolic pathways in lymphocytes and leukemia cells. The long-term goal is to identify therapeutic targets for immunological diseases and cancer. Three areas of focus on the lab are: (1) Function of PI3K/mTOR/eIF4F pathway components in immune cells; (2) Targeting the PI3K/mTOR/eIF4F pathway in leukemia and autoimmune diseases (3) Repurposing statins to enhance killing of blood cancer cells by BH3 mimetics such as venetoclax. Dr. Fruman previously served as Associate Director of the Institute for Immunology, and is currently Director of the UCI Cancer Research Institute.